



Express Mail No.: EV 335 855 710 US

#8  
TECH CENTER 1600/2900  
JUL 0 2 2003  
7/11

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Application of: Satoh et al.

Confirmation No.: 6771

Application No.: 10/004,645

Group Art Unit: 1617

Filed: December 4, 2001

Examiner: J. Kim

For: ANILINOPYRIMIDINE  
DERIVATIVES AS JNK  
INHIBITORS AND  
COMPOSITIONS AND  
METHODS RELATED THERETO

Attorney Docket No.: 10624-050-999

**RESPONSE TO RESTRICTION REQUIREMENT  
WITH TRAVERSE UNDER 37 C.F.R. §1.143**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

This responds to the Office Action mailed March 25, 2003. Applicants concurrently submit herewith: (a) a Supplemental Information Disclosure Statement and Form PTO-1449 listing references **DG-DK** (a copy of each being enclosed); and (2) a Petition for Extension of Time Under C.F.R. §1.136(a) two (2) months with provision for fee (in duplicate).

**REMARKS**

A Restriction Requirement under 35 U.S.C. §121 has been entered in the present application. The Restriction Requirement identifies five groups:

Group I. Claims 1-3 and 13-15, drawn to a method for treating an inflammatory or autoimmune condition comprising administering a compound having the structure set forth in claims 1 and 13;

Group II. Claims 1, 4, 5, 7 and 18, drawn to a method for treating a cardiovascular, metabolic or ischemic condition comprising administering a compound having the structure set forth in claims 1 and 17;

Group III. Claims 1, 6-8 and 19-21, drawn to a method for treating a infectious disease comprising administering a compound having the structure set forth in claims 1 and 19;

Group IV. Claims 1, 9, 12 and 22-25, drawn to a method for treating a cancer comprising administering a compound having the structure set forth in claims 1 and 22; and

Group V. Claims 1, 11 and 26, drawn to a method for treating stroke, epilepsy, and Alzheimer's disease comprising administering a compound having the structure set forth in claims 1 and 26.

Applicants respectfully traverse the restriction requirement and submit that a search related to methods for treatment comprising the administration of the compounds of the present claims would not impose an undue burden on the Examiner.

In order to be fully responsive, however, Applicants elect, with traverse, Group II, Claims 1, 4, 5, 7 and 18, drawn to a method for treating a cardiovascular, metabolic or ischemic condition comprising administering a compound having the structure set forth in claims 1 and 17, without prejudice to Applicants' right to prosecute any non-elected subject matter in one or more continuation, continuation-in-part or divisional applications.

No fee is believed to be due in connection with this response other than that for the extension of time; however, should any other fee be required, Applicant hereby authorizes that such fee be charged to Deposit Account No. 16-1150.

Date: June 25, 2003

Respectfully submitted,  
*Anthony M. Insogna, N.Y. No. 35,203*  
*By: Michael E. Lutz, N.Y. No. 36,343*  
*35,203*

Anthony M. Insogna (Reg. No.)

**PENNIE & EDMONDS LLP**  
1155 Avenue of the Americas  
New York, New York 10036-2711  
(212) 790-9090

Enclosures